SUBSCRIBE TO OUR FREE NEWSLETTER
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
5
#000000
#FFFFFF
5
#000000
#FFFFFF
Officials Warn of Possible Second Outbreak as Ebola Confirmed in Fifth Country
Japan awaits green light to supply untested drug as report from the World Health Organization highlights factors that have led to underestimated epidemic
Aug 25, 2014
Scientists are racing to confirm if an outbreak of Ebola in the Democratic Republic of Congo, which officials confirmed on Sunday, is a different strain than that which has killed nearly 1,500 people in Guinea, Liberia, Sierra Leone and Nigeria, potentially raising the specter of the crisis to two deadly outbreaks.
At a Sunday press briefing, DRC Health Minister Felix Kabange Numbi declared an "Ebola epidemic in the region of Djera, in the territory of Boende in the province of Equateur," Reuters reports, saying that two cases had tested positive for the deadly virus.
Numbi said that one case had tested positive for the Sudanese strain of the disease while the second was a mixture between a Sudanese strain and the more lethal Zaire strain, which has been linked to the outbreak in West Africa.
Following Numbi's announcement, officials with the World Health Organization said that the results had yet to be verified by the international health body and that results from a second lab are expected as early as Monday. However, Gregory Hartl, head of Public Relations, did say that the confirmation of a second strain would mean there is a second epidemic of the deadly disease.
The Ebola virus was first discovered in 1976 in the very same regional forest area of DRC as the current reported outbreak.
According to an update by the World Health Organization, as of Friday there have been 2,615 confirmed cases of the disease and 1,427 deaths.
On Friday, WHO issued a statement explaining how the fast-moving outbreak has been significantly underestimated, particularly in Liberia and Sierra Leone.
The statement cites as contributing factors both fear of western health care workers and the stigma of being placed in isolation at one of the quarantine centers, which recent reports described as having limited access to food and health care and resembling the "plague villages" of medieval Europe.
WHO issued an additional statement on Monday calling attention to the "unprecedented" number of health care workers who have been infected with the virus, citing a lack of protective equipment and early misdiagnosis at health treatment centers.
Japan is reportedly waiting for WHO approval to provide thousands of doses of the anti-influenza drug favipiravir, known as Avigan, for the possible treatment of Ebola.
Though Avigan has not been proven to be effective against Ebola, Takao Aoki, spokesman for Fujifilm Holdings Corp which developed the drug, said Ebola and influenza viruses are the same general type, and a similar response can theoretically be expected from Ebola.
According to Aoki, the company has enough stock of favipiravir for more than 20,000 patients.
An Urgent Message From Our Co-Founder
Dear Common Dreams reader, It’s been nearly 30 years since I co-founded Common Dreams with my late wife, Lina Newhouser. We had the radical notion that journalism should serve the public good, not corporate profits. It was clear to us from the outset what it would take to build such a project. No paid advertisements. No corporate sponsors. No millionaire publisher telling us what to think or do. Many people said we wouldn't last a year, but we proved those doubters wrong. Together with a tremendous team of journalists and dedicated staff, we built an independent media outlet free from the constraints of profits and corporate control. Our mission has always been simple: To inform. To inspire. To ignite change for the common good. Building Common Dreams was not easy. Our survival was never guaranteed. When you take on the most powerful forces—Wall Street greed, fossil fuel industry destruction, Big Tech lobbyists, and uber-rich oligarchs who have spent billions upon billions rigging the economy and democracy in their favor—the only bulwark you have is supporters who believe in your work. But here’s the urgent message from me today. It's never been this bad out there. And it's never been this hard to keep us going. At the very moment Common Dreams is most needed, the threats we face are intensifying. We need your support now more than ever. We don't accept corporate advertising and never will. We don't have a paywall because we don't think people should be blocked from critical news based on their ability to pay. Everything we do is funded by the donations of readers like you. When everyone does the little they can afford, we are strong. But if that support retreats or dries up, so do we. Will you donate now to make sure Common Dreams not only survives but thrives? —Craig Brown, Co-founder |
Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.
Lauren McCauley
Lauren McCauley is a former senior editor for Common Dreams covering national and international politics and progressive news. She is now the Editor of Maine Morning Star. Lauren also helped produce a number of documentary films, including the award-winning Soundtrack for a Revolution and The Hollywood Complex, as well as one currently in production about civil rights icon James Meredith. Her writing has been featured on Newsweek, BillMoyers.com, TruthDig, Truthout, In These Times, and Extra! the newsletter of Fairness and Accuracy in Reporting. She currently lives in Kennebunk, Maine with her husband, two children, a dog, and several chickens.
Scientists are racing to confirm if an outbreak of Ebola in the Democratic Republic of Congo, which officials confirmed on Sunday, is a different strain than that which has killed nearly 1,500 people in Guinea, Liberia, Sierra Leone and Nigeria, potentially raising the specter of the crisis to two deadly outbreaks.
At a Sunday press briefing, DRC Health Minister Felix Kabange Numbi declared an "Ebola epidemic in the region of Djera, in the territory of Boende in the province of Equateur," Reuters reports, saying that two cases had tested positive for the deadly virus.
Numbi said that one case had tested positive for the Sudanese strain of the disease while the second was a mixture between a Sudanese strain and the more lethal Zaire strain, which has been linked to the outbreak in West Africa.
Following Numbi's announcement, officials with the World Health Organization said that the results had yet to be verified by the international health body and that results from a second lab are expected as early as Monday. However, Gregory Hartl, head of Public Relations, did say that the confirmation of a second strain would mean there is a second epidemic of the deadly disease.
The Ebola virus was first discovered in 1976 in the very same regional forest area of DRC as the current reported outbreak.
According to an update by the World Health Organization, as of Friday there have been 2,615 confirmed cases of the disease and 1,427 deaths.
On Friday, WHO issued a statement explaining how the fast-moving outbreak has been significantly underestimated, particularly in Liberia and Sierra Leone.
The statement cites as contributing factors both fear of western health care workers and the stigma of being placed in isolation at one of the quarantine centers, which recent reports described as having limited access to food and health care and resembling the "plague villages" of medieval Europe.
WHO issued an additional statement on Monday calling attention to the "unprecedented" number of health care workers who have been infected with the virus, citing a lack of protective equipment and early misdiagnosis at health treatment centers.
Japan is reportedly waiting for WHO approval to provide thousands of doses of the anti-influenza drug favipiravir, known as Avigan, for the possible treatment of Ebola.
Though Avigan has not been proven to be effective against Ebola, Takao Aoki, spokesman for Fujifilm Holdings Corp which developed the drug, said Ebola and influenza viruses are the same general type, and a similar response can theoretically be expected from Ebola.
According to Aoki, the company has enough stock of favipiravir for more than 20,000 patients.
Lauren McCauley
Lauren McCauley is a former senior editor for Common Dreams covering national and international politics and progressive news. She is now the Editor of Maine Morning Star. Lauren also helped produce a number of documentary films, including the award-winning Soundtrack for a Revolution and The Hollywood Complex, as well as one currently in production about civil rights icon James Meredith. Her writing has been featured on Newsweek, BillMoyers.com, TruthDig, Truthout, In These Times, and Extra! the newsletter of Fairness and Accuracy in Reporting. She currently lives in Kennebunk, Maine with her husband, two children, a dog, and several chickens.
Scientists are racing to confirm if an outbreak of Ebola in the Democratic Republic of Congo, which officials confirmed on Sunday, is a different strain than that which has killed nearly 1,500 people in Guinea, Liberia, Sierra Leone and Nigeria, potentially raising the specter of the crisis to two deadly outbreaks.
At a Sunday press briefing, DRC Health Minister Felix Kabange Numbi declared an "Ebola epidemic in the region of Djera, in the territory of Boende in the province of Equateur," Reuters reports, saying that two cases had tested positive for the deadly virus.
Numbi said that one case had tested positive for the Sudanese strain of the disease while the second was a mixture between a Sudanese strain and the more lethal Zaire strain, which has been linked to the outbreak in West Africa.
Following Numbi's announcement, officials with the World Health Organization said that the results had yet to be verified by the international health body and that results from a second lab are expected as early as Monday. However, Gregory Hartl, head of Public Relations, did say that the confirmation of a second strain would mean there is a second epidemic of the deadly disease.
The Ebola virus was first discovered in 1976 in the very same regional forest area of DRC as the current reported outbreak.
According to an update by the World Health Organization, as of Friday there have been 2,615 confirmed cases of the disease and 1,427 deaths.
On Friday, WHO issued a statement explaining how the fast-moving outbreak has been significantly underestimated, particularly in Liberia and Sierra Leone.
The statement cites as contributing factors both fear of western health care workers and the stigma of being placed in isolation at one of the quarantine centers, which recent reports described as having limited access to food and health care and resembling the "plague villages" of medieval Europe.
WHO issued an additional statement on Monday calling attention to the "unprecedented" number of health care workers who have been infected with the virus, citing a lack of protective equipment and early misdiagnosis at health treatment centers.
Japan is reportedly waiting for WHO approval to provide thousands of doses of the anti-influenza drug favipiravir, known as Avigan, for the possible treatment of Ebola.
Though Avigan has not been proven to be effective against Ebola, Takao Aoki, spokesman for Fujifilm Holdings Corp which developed the drug, said Ebola and influenza viruses are the same general type, and a similar response can theoretically be expected from Ebola.
According to Aoki, the company has enough stock of favipiravir for more than 20,000 patients.
We've had enough. The 1% own and operate the corporate media. They are doing everything they can to defend the status quo, squash dissent and protect the wealthy and the powerful. The Common Dreams media model is different. We cover the news that matters to the 99%. Our mission? To inform. To inspire. To ignite change for the common good. How? Nonprofit. Independent. Reader-supported. Free to read. Free to republish. Free to share. With no advertising. No paywalls. No selling of your data. Thousands of small donations fund our newsroom and allow us to continue publishing. Can you chip in? We can't do it without you. Thank you.